GlassScriptPhysician profile
Michael V Dao
NPI 1205838588
$17,653.43
in general payments reported to CMS, 2019-2025
52 companies · $2,015 in 2025
The $2,015 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,225 · 2020: $2,538 · 2021: $3,395 · 2022: $2,781 · 2023: $2,504 · 2024: $2,196 · 2025: $2,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,698 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,697.70 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,929.02 | 2019-2025 | Ubrelvy, Linzess, Vraylar |
| Novo Nordisk INC | $1,809.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,640.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $1,407.61 | 2021 | |
| Lilly USA, LLC | $1,275.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,243.48 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $989.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $906.55 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $565.64 | 2019-2023 | Belsomra, Steglatro, Segluromet |
| Pfizer INC. | $504.04 | 2020-2025 | |
| Amarin Pharma, INC. | $493.69 | 2019-2023 | |
| Antares Pharma, INC. | $416.27 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Allergan, INC. | $389.07 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $382.62 | 2019-2024 | Trulance, Xifaxan |
| Kowa Pharmaceuticals America, INC. | $351.83 | 2020-2025 | Livalo, Seglentis, Zoryve |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.